Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis

First filed May 2016, updated December 2018

CATEGORIES: Lupus Nephritis

The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the dose-response relationship within the therapeutic range, and select the target dose for phase III development.

Study sponsor: Boehringer Ingelheim

To Learn More Contact
Boehringer Ingelheim Call Center at1-800-243-0127 or  clintriage.rdg@boehringer-ingelheim.com
ClinicalTrials.gov identifier: NCT02770170

Learn More

Dynamic Imaging of Variation in Lupus Nephritis (DIVINE)

First filed April 2017, updated December 2018

CATEGORIES: Lupus Nephritis

This multicenter trial is using a variety of kidney imaging tools, including magnetic resonance imaging to evaluate and monitor the kidneys of patients with lupus nephritis (LN) to determine if these non-invasive tools could replace surgical biopsy.

To Learn More Contact
Rebecca Bender at 434-477-2675 or rebeccabender@ampel.org
ClinicalTrials.gov identifier: NCT03180021

Learn More

A Phase 2 Safety and Efficacy Study of Filgotinib and GS-9876 in Participants with Lupus Membranous Nephropathy (LMN)

First filed Sept. 2017, verified December 2018

CATEGORIES: Lupus Nephritis

The purpose of thisPhase 3 study is assess the long-term safety and tolerability of voclosporin compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with lupus nephritis (LN).

To Learn More Contact
GS-US-437-4093@gilead.com 
ClinicalTrials.gov identifier: NCT03285711

Learn More

Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin (AURORA2)

First filed July 2018, verified August 2018

CATEGORIES: Lupus Nephritis

The purpose of thisPhase 3 study is assess the long-term safety and tolerability of voclosporin compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with lupus nephritis (LN).

To Learn More Contact
Antonia Coeshall at 441962715493 or acoeshall@auriniapharma.com
Laura Lisk at (0)7790555604 or llisk@auriniapharma.com
ClinicalTrials.gov identifier: NCT03597464

Learn More